Janus Henderson Group PLC Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Janus Henderson Group PLC lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,790 shares of the company’s stock after selling 1,749 shares during the quarter. Janus Henderson Group PLC’s holdings in IDEXX Laboratories were worth $6,062,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Harbour Investments Inc. increased its position in shares of IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after purchasing an additional 16 shares in the last quarter. Prime Capital Investment Advisors LLC lifted its holdings in IDEXX Laboratories by 0.5% in the 4th quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock valued at $2,654,000 after purchasing an additional 18 shares in the last quarter. Pinnacle Associates Ltd. lifted its holdings in IDEXX Laboratories by 1.5% in the 4th quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock valued at $830,000 after purchasing an additional 18 shares in the last quarter. Triad Wealth Partners LLC boosted its stake in IDEXX Laboratories by 3.1% during the 1st quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock worth $337,000 after purchasing an additional 18 shares during the last quarter. Finally, Advisory Services Network LLC boosted its stake in IDEXX Laboratories by 2.5% during the 4th quarter. Advisory Services Network LLC now owns 752 shares of the company’s stock worth $509,000 after purchasing an additional 18 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.9%

NASDAQ IDXX opened at $590.00 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The business’s fifty day simple moving average is $559.26 and its 200-day simple moving average is $585.78. The firm has a market cap of $46.48 billion, a PE ratio of 41.49, a P/E/G ratio of 3.17 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the prior year, the firm posted $3.50 earnings per share. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Citigroup boosted their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, UBS Group raised their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $756.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.